IGF2BP2 Drives Cell Cycle Progression in Triple-Negative Breast Cancer by Recruiting EIF4A1 to Promote the m6A-Modified CDK6 Translation Initiation Process

IGF2BP2 is a new identified N6-methyladenosine (m6A) reader and associated with poor prognosis in many tumors. However, its role and related mechanism in breast cancer, especially in triple-negative breast cancer (TNBC), remains unclear. In this study, it is found that IGF2BP2 is highly expressed in TNBC due to the lower methylation level in its promoter region. Functional and mechanical studies displayed that IGF2BP2 could promote TNBC proliferation and the G1/S phase transition of the cell cycle via directly regulating CDK6 in an m6A-dependent manner. Surprising, the regulation of protein levels of CDK6 by IGF2BP2 is related to the changes in translation rate during translation initiation, rather than mRNA stability. Moreover, EIF4A1 is found to be recruited by IGF2BP2 to promote the translation output of CDK6, providing new evidence for a regulatory role of IGF2BP2 between m6A methylation and translation. Downregulation of IGF2BP2 in TNBC cell could enhance the sensitivity to abemaciclib, a CDK4/6 inhibitor. To sum up, our study revealed IGF2BP2 could facilitate the translation output of CDK6 via recruiting EIF4A1 and also provided a potential therapeutic target for the diagnosis and treatment of TNBC, as well as a new strategy for broadening the drug indications for CDK4/6 inhibitors. IGF2BP2, an m6A reader, is found to be highly expressed in triple-negative breast cancer (TNBC), which may be related to the lower methylation level in its promoter region caused by TET3. This study revealed that IGF2BP2 facilitated the translation output of CDK6 via recruiting EIF4A1 to promote TNBC proliferation, and targeting IGF2BP2 increased the sensitivity of TNBC to CDK4/6 inhibitors.image

Automated summary

IGF2BP2 is highly expressed in TNBC and promotes TNBC proliferation by recruiting EIF4A1 to facilitate the translation output of CDK6. Downregulation of IGF2BP2 increases TNBC sensitivity to CDK4/6 inhibitors, providing a new strategy for TNBC treatment.